SG3 Management’s Gossamer Bio GOSS Stock Holding History

SG3 Management’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,000	Closed	-$120K	–	270
2022 Q3	$120K	Sell	10,000 -10,000	-50%	-$124K	0.02%	221
2022 Q2	$167K	Buy	+20,000	New	+$155K	0.02%	291

Other funds holding GOSS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SG3 Management's GOSS Position: Q4 2022 in Review

SG3 Management sold out of Gossamer Bio (GOSS) in Q4 2022, closing a stake of 7,500 shares — an estimated $89.8K sold.

SG3 Management first reported a position in GOSS in Q3 2020 and held it in 5 quarters. The position peaked at $207K in Q1 2022. 120 funds tracked by Wall St. Rank hold GOSS as of Q4 2022.

SG3 Management reported no remaining Gossamer Bio position as of Q4 2022 after selling out during the quarter.
SG3 Management sold 7,500 Gossamer Bio shares in Q4 2022, an estimated $89.8K.
SG3 Management first reported a position in Gossamer Bio in Q3 2020 and held it in 5 quarters.
SG3 Management's Gossamer Bio position peaked at $207K in Q1 2022.
120 funds tracked by Wall St. Rank held Gossamer Bio as of Q4 2022.

Based on SG3 Management's 13F filing for Q4 2022, filed 14 Feb 2023.